NATAP: Resistance Wkp Report/New HIV Drugs-Mark Wainberg

[Guest guest]

Topics1. Persistence, Reservoirs, and Elimination Strategies2. Resistance to new antiretroviral compoundsBoehringer Ingelheim: new series of nucleotide competing reverse transcriptase inhibitorsBristol Myers Squibb: new nucleoside BMS-98600, novel thymidine analogue that is currently in phase IIb clinical trialsGilead: ElvitagravirViiV: DolutegravirBristol Myers Squibb: novel attachment inhibitor BMS-6265293. Mechanisms of HIV drug resistanceSubject: NATAP: Resistance Wkp Report/New HIV Drugs-Mark WainbergIntl Wksp HIV/Hep Drug Resist: Report from International Workshop on HIV & Hepatitis Virus Drug Resistance 5-9 June 2012, Sitges, Spain - Written for NATAP by Mark A. Wainberg, PhD, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada

(06/18/12)